Defibrillation effectiveness and safety of the shock waveform used in a contemporary wearable cardioverter defibrillator: Results from animal and human studies

PLoS One. 2023 Mar 14;18(3):e0281340. doi: 10.1371/journal.pone.0281340. eCollection 2023.

Abstract

Introduction: The wearable cardioverter defibrillator (WCD) is used to protect patients at risk for sudden cardiac arrest. We examined defibrillation efficacy and safety of a biphasic truncated exponential waveform designed for use in a contemporary WCD in three animal studies and a human study.

Methods: Animal (swine) studies: #1: Efficacy comparison of a 170J BTE waveform (SHOCK A) to a 150J BTE waveform (SHOCK B) that approximates another commercially available waveform. Primary endpoint first shock success rate. #2: Efficacy comparison of the two waveforms at attenuated charge voltages in swine at three prespecified impedances. Primary endpoint first shock success rate. #3: Safety comparison of SHOCK A and SHOCK B in swine. Primary endpoint cardiac biomarker level changes baseline to 6 and 24 hours post-shock. Human Study: Efficacy comparison of SHOCK A to prespecified goal and safety evaluation. Primary endpoint cumulative first and second shock success rate. Safety endpoint adverse events.

Results: Animal Studies #1: 120 VF episodes in six swine. First shock success rates for SHOCK A and SHOCK B were 100%; SHOCK A non-inferior to SHOCK B (entire 95% CI of rate difference above -10% margin, p < .001). #2: 2,160 VF episodes in thirty-six swine. Attenuated SHOCK A was non-inferior to attenuated SHOCK B at each impedance (entire 95% CI of rate difference above -10% margin, p < .001). #3: Ten swine, five shocked five times each with SHOCK A, five shocked five times each with SHOCK B. No significant difference in troponin I (p = 0.658) or creatine phosphokinase (p = 0.855) changes from baseline between SHOCK A and SHOCK B. Human Study: Thirteen patients, 100% VF conversion rate. Mild skin irritation from adhesive defibrillation pads in three patients.

Conclusions: The BTE waveform effectively and safely terminated induced VF in swine and a small sample in humans.

Trial registration: Human study clinical trial registration: URL: https://clinicaltrials.gov; Unique identifier: NCT04132466.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Defibrillators
  • Electric Countershock / adverse effects
  • Electric Countershock / methods
  • Humans
  • Swine
  • Treatment Outcome
  • Ventricular Fibrillation* / therapy
  • Wearable Electronic Devices*

Associated data

  • ClinicalTrials.gov/NCT04132466
  • figshare/10.6084/m9.figshare.21964544.v1

Grants and funding

Kestra Medical Technologies, Inc., (JS, KB, RR, LG) https://kestramedical.com/ The sponsor collaborated in the design and conduct of the study; preparation, review, or approval of the manuscript. The specific roles of authors are articulated in the ‘author contributions’ section.